Vanguard Global Advisers’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$943K Buy
38,569
+505
+1% +$14.1K ﹤0.01% 1742
2026
Q2
$1.31M Sell
38,064
-1,348
-3% -$40.7K ﹤0.01% 1574
2026
Q1
$939K Buy
+39,412
New +$1.09M ﹤0.01% 1683

Other funds holding BEAM

Vanguard Global Advisers's BEAM Position: Q3 2026 in Review

Vanguard Global Advisers increased its Beam Therapeutics (BEAM) stake by 1.3% in Q3 2026, buying an estimated $14.1K and bringing the position to 38,569 shares worth $943K. The position accounts for ﹤0.01% of the portfolio, ranked #1742.

Vanguard Global Advisers first reported a position in BEAM in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.31M in Q2 2026. 264 funds tracked by Wall St. Rank hold BEAM as of Q3 2026.

  • Vanguard Global Advisers held 38,569 shares of Beam Therapeutics worth $943K as of Q3 2026.
  • Vanguard Global Advisers bought 505 Beam Therapeutics shares in Q3 2026, an estimated $14.1K.
  • Beam Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #1742 holding.
  • Vanguard Global Advisers first reported a position in Beam Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Beam Therapeutics position peaked at $1.31M in Q2 2026.
  • 264 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.